Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has announced a share repurchase plan using raised funds, self-owned funds, and self-raised funds through centralized bidding, with a total repurchase amount between RMB 100 million and RMB 200 million [2][3]. Summary by Sections Share Repurchase Plan - The company plans to use a total of no less than RMB 100 million and no more than RMB 200 million for the share repurchase, with at least RMB 30 million and no more than RMB 60 million coming from raised funds [2]. - The repurchased shares will be used for cancellation to reduce registered capital and for employee stock ownership plans or equity incentives [2]. Price Adjustment - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price has been adjusted from RMB 45.50 per share to RMB 34.84 per share, effective from July 14, 2025 [3]. Repurchase Details - The repurchase plan includes a target quantity of shares to be repurchased ranging from 2,009,185 to 4,018,369 shares, which represents approximately 1.75% to 3.50% of the company's total shares [4]. - As of July 31, 2025, the company has not yet implemented the share repurchase [4].

证券日报网讯7月31日晚间，华兰股份（301093）发布公告称，截至2025年7月31日，公司尚未实施本次 股份回购。 ...

Core Viewpoint - Recently, the company announced that its subsidiary has opened a dedicated settlement account for cash management products related to fundraising [2] Group 1 - The company is actively managing its fundraising efforts through the establishment of a specialized account [2] - This move indicates the company's strategy to optimize cash management and enhance financial flexibility [2]

Group 1 - The core viewpoint of the news highlights the performance and valuation of Hualan Co., with a closing price of 26.42 yuan and a rolling PE ratio of 75.75 times, indicating a significant premium over the industry average [1] - Hualan Co. has a total market capitalization of 4.338 billion yuan, ranking 95th in the medical device industry, which has an average PE ratio of 54.89 times and a median of 37.06 times [1] - On July 31, Hualan Co. experienced a net inflow of 10.9912 million yuan in main funds, with a total inflow of 4.2241 million yuan over the past five days, indicating positive investor sentiment [1] Group 2 - Hualan Co. specializes in the research, production, and sales of packaging materials for injectable drugs, with key products including film-coated stoppers and conventional stoppers [2] - The company has received several recognitions, including being designated as a "High-tech Enterprise" and achieving "AAA-level Quality Credit Enterprise" status in Jiangsu Province [2] - Hualan Co. has been involved in the development of national standards for injectable packaging materials and has received FDA DMF registration for its film-coated stoppers [2] Group 3 - In the latest quarterly report for Q1 2025, Hualan Co. reported an operating income of 146 million yuan, a year-on-year increase of 15.03%, and a net profit of 18.3792 million yuan, reflecting a year-on-year growth of 72.10% [3] - The company's gross profit margin stands at 37.68%, indicating a strong profitability position within the industry [3] - Comparatively, Hualan Co.'s PE ratios (TTM and static) are significantly higher than the industry averages, with the industry average PE at 54.89 times and the median at 37.06 times [3]

格隆汇7月31日丨华兰股份(301093.SZ)公布，截至2025年7月31日，公司尚未实施本次股份回购。 ...

回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301093 证券简称：华兰股份 公告编号：2025-078 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025年 7月 12日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份的回 购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募资金不 ...

关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第二十七次 会议、2024 年第七次临时股东大会，审议通过了《关于使用部分闲置募集资金和自 有资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 130,000 万元的 闲置募集资金（含超募资金，下同）和自有资金进行现金管理，其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效期为公司股东大会审议通 过之日起 12 个月内，上述额度在有效期内可循环滚动使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯网（www.cninfo.com.cn）上披露 的《关于使用部分闲置募集资金和自有资金进行现金管理的公告》（公告编号：2024- 111）。 近日，公司子公司开立了募集资金现金管理产品专用结算账户，现就具体情况公 告如下： 证券 ...

Group 1 - Company closed at 26.13 yuan on July 29, down 1.25%, with a rolling PE ratio of 74.91 times and a total market value of 4.291 billion yuan [1] - The average PE ratio in the medical device industry is 55.46 times, with a median of 37.74 times, placing the company at the 96th position in the industry ranking [1] - On July 29, the company experienced a net outflow of 1.2299 million yuan in principal funds, with a total outflow of 13.0329 million yuan over the past five days [1] Group 2 - The main business of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. includes the R&D, production, and sales of packaging materials for injectable drugs, primarily focusing on film-coated rubber stoppers and conventional rubber stoppers [2] - The company has received various recognitions, including being designated as a "Jiangsu Provincial Enterprise Technology Center" in 2012 and obtaining the "High-tech Enterprise Certificate" in 2020 [2] - The company's film-coated rubber stoppers have received DMF registration from the FDA, and it has participated in the drafting of national standards for injectable packaging materials [2] Group 3 - In the latest quarterly report for Q1 2025, the company achieved an operating income of 146 million yuan, a year-on-year increase of 15.03%, and a net profit of 18.3792 million yuan, a year-on-year increase of 72.10%, with a gross profit margin of 37.68% [3] - The company's PE ratio (TTM) is 74.91, while the industry average is 55.46, indicating a higher valuation compared to peers [3] - The company ranks among various competitors in the medical device industry, with notable companies like Jiuan Medical and Yingke Medical having significantly lower PE ratios [3]

Industry Overview - As of July 17, the medical device industry rose by 0.78%, with a net capital outflow of 178.58 million [1] - A total of 89 stocks in the sector increased, while 31 stocks decreased [1] Top Decliners - The top ten decliners in the sector included: - ST Kelly (-6.72%) - Haooubo (-4.36%) - Tailin Biology (-2.04%) - Mountain Outside Mountain (-1.71%) - Botuo Biology (-1.59%) - Yirui Technology (-1.35%) - DR Sanyou Medical (-1.31%) - Jihigh Development (-1.24%) - Anxu Biology (-1.21%) - Aidi Te (-0.89%) [1][1] Notable Gainers - Notable gainers included: - Anjisi: 7.36% increase with a net capital outflow of 12.83 million - Hualan Co.: 5.22% increase with a net capital outflow of 5.90 million - Xinmai Medical: 5.11% increase with a net capital inflow of 6.21 million - Nanwei Medical: 4.45% increase with a net capital inflow of 19.79 million [1][1][1] Market Sentiment - The overall market sentiment in the medical device sector showed a mixed performance with significant capital outflows from certain stocks while others attracted investment [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-076 江苏华兰药用新材料股份有限公司 关于公司取得金融机构股票回购专项贷款承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 本次回购股份的基本情况 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...